Receptor transmembrane domains (TMDs) are crucially involved in relaying ligand information from extracellular to intracellular spaces and represent attractive targets for small molecule manipulation of receptor function.
Screening a library of over 8,000 drug-like compounds with an assay based on the TMD of death receptor p75NTR, we identified a novel small molecule capable of inhibiting p75NTR-mediated migration of human melanoma cells. Employing medicinal chemistry, a more potent derivative termed Np75-4A22 was identified that blocked nerve growth factor (NGF)-mediated melanoma invasion at sub-micromolar concentrations. The specific interaction of Np75-4A22 with the p75NTR TMD was confirmed by 2D NMR. Mechanistically, Np75-4A22 was found to antagonize NGF-mediated recruitment of the actin-bundling protein fascin to p75NTR, fascin association with the actin cytoskeleton and filopodia formation. Importantly, preclinical assessment of Np75-4A22 showed high oral bioavailability, low toxicity, and significant inhibition of melanoma lung invasion in mice.
These results support further development of this approach as an alternative or complementary strategy for melanoma cancer patients that do not respond to conventional chemotherapy or immune checkpoint inhibitors.
The paper has been published in EMBO Molecular Medicine
Read the full paper HERE
